Announcement • Jun 24
Thalia Therapeutics Plc, Annual General Meeting, Jul 17, 2026 Thalia Therapeutics Plc, Annual General Meeting, Jul 17, 2026. Location: the offices of arch law limited, huckletree bishopsgate, 8 bishopsgate, london ec2n 4bq United Kingdom Reported Earnings • Jun 24
Full year 2025 earnings released: UK£0.002 loss per share (vs UK£0.003 loss in FY 2024) Full year 2025 results: UK£0.002 loss per share. Net loss: UK£1.21m (loss widened 14% from FY 2024). New Risk • Apr 13
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 15% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Shareholders have been substantially diluted in the past year (55% increase in shares outstanding). Revenue is less than US$1m (UK£7.1k revenue, or US$9.5k). Market cap is less than US$10m (UK£5.62m market cap, or US$7.59m). Minor Risk Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). New Risk • Apr 13
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (55% increase in shares outstanding). Revenue is less than US$1m (UK£7.1k revenue, or US$9.5k). Market cap is less than US$10m (UK£3.75m market cap, or US$5.04m). Minor Risk Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Reported Earnings • Sep 28
First half 2025 earnings released: UK£0.001 loss per share (vs UK£0.002 loss in 1H 2024) First half 2025 results: UK£0.001 loss per share. Net loss: UK£498.6k (loss widened 9.6% from 1H 2024). Announcement • Sep 22
N4 Pharma Plc Announces Further Details of its Collaboration with SRI on the Targeting Delivery of RNA into Cells Using Nuvec N4 Pharma plc announced further details of its collaboration with SRI on the targeted delivery of RNA into cells using Nuvec. Following detailed additional analysis, the resulting data are now shaping a new scope of work focused on utilising Nuvec for targeted treatments in oncology. The Company's collaboration combined SRI's targeting molecules with Nuvec successfully delivering therapeutic RNA ("siRNA") payloads to specific cell types, specifically non-small cell lung cancer cells. Key results: Precision targeting achieved: Nuvec particles were functionalised with a targeting molecule binding to a cell surface adhesion molecule (avb6) - a protein found at high levels in epithelial cancers such as lung, breast, prostate and pancreatic adenocarcinomas; Selective uptake confirmed: siRNA payloads were successfully delivered and active only by the targeted Nuvec particles compared to untargeted Nuvec, demonstrating that Nuvec can be directed to specific cell types; Broader validation of Nuvec: The findings strengthen the platform's potential as a differentiated delivery system for RNA therapeutics across multiple disease areas, including cancers of high unmet need such as lung and pancreatic cancers. challenges associated with the manufacturing and targeted delivery of RNA therapeutics are known to impact this market growth. Targeting RNA therapies to specific cells and tissues to maximise efficacy and reduce systemic toxicity is a holy grail for nucleic acid therapeutics developers and is challenging to achieve with established RNA delivery methods. In parallel to the successful targeting of Nuvec particles to cancer cells in collaboration with SRI, N4 Pharma has also demonstrated targeting of Nuvec to immune cells using mannose modification in its lead programme, N4 101, which is designed to be an orally delivered treatment for inflammatory bowel disease. Announcement • Sep 19
N4 Pharma Plc to Report First Half, 2025 Results on Sep 25, 2025 N4 Pharma Plc announced that they will report first half, 2025 results on Sep 25, 2025 New Risk • Sep 01
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Shareholders have been substantially diluted in the past year (111% increase in shares outstanding). Revenue is less than US$1m (UK£7.3k revenue, or US$9.9k). Market cap is less than US$10m (UK£4.79m market cap, or US$6.48m). Announcement • Jul 08
N4 Pharma plc Appoints Edward Wardleas Non-Executive Director N4 Pharma Plc announced the appointment of Edward Wardleas a Non-Executive Director of the Company with immediate effect. Edward is joining the Board as a representative of Northern Standard Limited, which is the Company's largest shareholder. Edward brings board-level experience of strategy, corporate governance and business development. Having founded and led multiple businesses, he is currently an investment adviser with Tracarta Limited and Northern Standard Limited, focusing on critical industries and cutting-edge technologies, as well as a Senior Business Development Executive at Ironveld plc. He joined the Board of AIM-listed TheraCryf plc, the clinical stage drug development company focusing on neuropsychiatry and oncology, as a Non-Executive Director in May 2025. The following information is disclosed pursuant to Rule 17 and Schedule Two paragraph (g) of the AIM Rules for Companies in relation to Edward James Norman Wardle, aged 34:Current Directorships/Partnerships: Theracryf plc; the Hammer Organization Limited; Otherworld Piccadilly Limited; the Dream Corporation Limited; Otherworld Dublin Limited. Past Directorships/Partnerships (Within 5 Years): Otherworld Manchester Limited; Otherworld Birmingham Limited. Announcement • Jun 07
N4 Pharma Plc, Annual General Meeting, Jun 30, 2025 N4 Pharma Plc, Annual General Meeting, Jun 30, 2025. Location: the offices of arch law limited, huckletree bishopsgate, 8 bishopsgate, ec2n 4bq, london United Kingdom Announcement • Jun 06
N4 Pharma Plc Announces Formation of Senior Leadership Team As announced on 27 May 2025, N4 Pharma Plc's newly configured Board is now supported by the formation of a Senior Leadership Team, reporting to Nigel Theobald, Chief Executive Officer,comprising leading expert consultants in drug development and research, commercial strategy, and pharmaceutical manufacturing. The team is made up as follows: Dr Fiona McLaughlin - Head of Research and Development: Dr Fiona McLaughlin is a highly experienced oncology drug developer and independent consultant, bringing over 25 years of experience in research and translational drug development in the pharmaceutical and biotech sectors, having led teams from early research through to clinical development. Fiona started her career at GSK and has subsequently held leadership positions in multiple biotech companies, including CSO of Avacta Therapeutics, VP New Opportunities at Algeta ASA (now Bayer), VP Translational Research at Antisoma plc and Director of Pre-clinical Development at BTG plc (now part of Boston Scientific). She is also a non-executive director of Hox Therapeutics. Fiona received a PhD from the Haematology Department at Cambridge University and has a BSc in Biochemistry from Glasgow University. Mark Edbrooke - Head of Strategy: Mark Edbrooke, PhD is an independent scientific consultant with a broad experience in pharmaceutical research and development. During 25 years at GlaxoSmithKline, he ran a transnational functional genomics department, and then set up and led GSK's therapeutic nucleic acid unit. He then joined AstraZeneca's Oncology Division for three years, working with Ionis and Moderna. Mark currently has a portfolio of clients, including UK and US-based investment companies, UK and European-based universities, and small biotechs, including being Head of Translational Research at Argonaute RNA Ltd., and on the Senior Advisory Board for Deep Genomics. Dr Simon Bennett - Commercial Director: Dr Simon Bennett is an independent consultant with over 28 years of experience in the bio-pharma industry. Over the last 15 years, Simon has worked with more than 70 clients of all sizes, from technology startups to Big Pharma, largely supporting business development and licensing, as well as technology scouting and fundraising. Simon has been involved in over 80 commercial deals and mentors and advises early-stage businesses and management teams, primarily in specialty pharma and biotech. Before moving into industry in 1997, Simon was a Wellcome Trust Research Fellow at the University of Oxford. Dr Margaret Courtney - Head of Chemistry, Manufacturing and Controls (CMC): Dr Margaret Courtney is an independent consultant with over 25 years of experience in transitioning active substances and drug products from the research laboratory into clinical studies and commercialisation. Margaret has worked in management positions in small biotech companies to large pharmaceutical organisations, and following on from her pharmacy degree and doctoral studies, has developed specific expertise in drug delivery systems. Currently, she is working with a range of clients and providing CMC strategic advice as well as selection and management of contract organisations. Announcement • Apr 24
N4 Pharma Plc has completed a Follow-on Equity Offering in the amount of £12.359907 million. N4 Pharma Plc has completed a Follow-on Equity Offering in the amount of £12.359907 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 142,780,350
Price\Range: £0.004
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 294,719,650
Price\Range: £0.04
Transaction Features: Subsequent Direct Listing New Risk • Apr 13
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 0.6% per year over the past 5 years. Shareholders have been substantially diluted in the past year (100% increase in shares outstanding). Revenue is less than US$1m (UK£5.9k revenue, or US$7.7k). Market cap is less than US$10m (UK£2.02m market cap, or US$2.64m). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Share price has been volatile over the past 3 months (10% average weekly change). New Risk • Jan 16
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 47% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 0.6% per year over the past 5 years. Shareholders have been substantially diluted in the past year (47% increase in shares outstanding). Revenue is less than US$1m (UK£5.9k revenue, or US$7.2k). Market cap is less than US$10m (UK£2.66m market cap, or US$3.25m). Announcement • Jan 08
N4 Pharma plc Announces Board and Committees Changes N4 Pharma Plc announced the appointment of Dr. Alastair Smith as an independent Non-Executive Director of the Company with immediate effect. In addition, David Templeton has retired as a Director of the Company with immediate effect due to personal reasons. Alastair was the founder and former Chief Executive Officer of Avacta Group plc ("Avacta"), an AIM-listed biotech company established as a spin-out from Leeds University in 2005 and listed on the London Stock Exchange AIM market in 2006. Over his tenure, Avacta grew into one of the leading AIM biotech companies comprising two divisions: a clinical stage oncology drug company advancing its proprietary pre CISIONTM tumour targeting platform and a diagnostics business executing an M&A-led growth strategy in Europe focused on healthcare professionals. Alastair joins the Company's remuneration and audit committees. Announcement • Dec 13
N4 Pharma plc Provides A Progress Update on the in Vitro Pre-Clinical Development of Its Lead Nuvec® Proof-Of-Concept Programme, N4 101 N4 Pharma Plc provided a progress update on the in vitro pre-clinical development of its lead Nuvec®? proof-of-concept programme, N4 101, an oral anti-inflammatory product for the treatment of Inflammatory Bowel Disease (IBD). The size of the global RNA therapeutics market was $13.7 billion in 2023 and is expected to reach $18.0 billion by 20281. challenges associated with the manufacturing and delivery of RNA therapeutics are known to impact this market growth - challenges which N4 Pharma is addressing with its Nuvec®? technology, aiming to become an industry leading delivery platform used by multiple pharmaceutical partners. N4 Pharma's oral IBD product, N4 101, is designed to showcase the key benefits of the Nuvec®? delivery technology where other approaches struggle: i) it can straightforwardly load multiple RNA therapeutics onto the same particle, ii) it protects the payload from enzyme degradation to allow oral delivery to the gut andiii) it can be functionalised to target specific cells. The Company has completed a series of in vitro experiments which clearly demonstrate these competitive advantages. Key Highlights: The efficiency of delivery and efficacy of an siRNA and an mRNA therapeutic used to treat IBD are demonstrably enhanced when delivered by targeted Nuvec®? particles compared with untargeted delivery; A Nuvec®? formulation dual loaded with both therapeutics at the same time shows equivalent efficacy to the separate treatments; A patent has been filed reflecting the clear advantages of Nuvec®? for targeting and dual loading; and, The Company is awaiting ethics committee approval to build on these excellent in vitro data and begin an in vivo study in an appropriate animal model early in 2025 at the University of Queensland. Announcement • Dec 04
N4 Pharma Plc Announces New Patent Filing N4 Pharma Plc announce it has filed a new patent for its oral anti-inflammatoryIrritable Bowel Disease (‘IBD’) product in early pre-clinical development. The orally delivered product uses the unique capabilities of the Company's Nuvec delivery system to target the macrophage cells responsible for the inflammation associated with IBD. Each Nuvec nanoparticle contains two separate RNA, an siRNA to inhibit the production of TNF-alpha and an mRNA to promote the body's natural anti-inflammatory defenses. By delivering these RNA together locally in the gut, the symptoms of IBD can be more readily treated. The patent has been filed with the UK patent office. Announcement • Sep 09
N4 Pharma plc Announces Appointment of Michael Palfreyman as Independent Non-Executive Director N4 Pharma Plc announced the appointment of Dr. Michael Palfreyman as an independent Non-Executive Director of the Company with immediate effect. Dr. Palfreyman has more than four decades of successful drug discovery and development experience in several therapeutic areas with two major pharmaceutical companies (Marrion Meryl Dow, now Sanofi, and Beecham Pharmaceuticals, now GSK) and has co-founded and developed several biotechnology companies including, among others, Co-Founder of Scriptgen (Anadys) Pharmaceuticals which was sold to Roche in 2011 for USD 230 million and Co-Founder and CSO of Amorsa Therapeutics Inc. developing novel treatments for depression and pain where he oversaw a successful USD 180 million exit. Dr. Palfreyman currently advises Cybin Inc. listed on the New York Exchange and was Chairman and COO to Adelia Therapeutics Inc. that merged in 2020 to form the current Cybin Inc. Dr. Palfreyman has served on various scientific advisory boards and has been an adviser to The Forsyth Institute, Stanford Research Institute, NeuroNascent, MAK Scientific and Jasco Pharmaceuticals. Dr. Palfreymanis an Emeritus Fellow of the American College of Neuropsychopharmacology. He is co-inventor on 55 issued US and European patents, multiple pending patents, and has co-authored over 150 scientific articles and book chapters. Dr. Palfreyman joins the Company's remuneration and audit committees. New Risk • Jun 10
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 69% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£1.2m free cash flow). Earnings have declined by 1.5% per year over the past 5 years. Shareholders have been substantially diluted in the past year (69% increase in shares outstanding). Revenue is less than US$1m (UK£2.0k revenue, or US$2.5k). Market cap is less than US$10m (UK£2.17m market cap, or US$2.76m). Minor Risk Share price has been volatile over the past 3 months (11% average weekly change). New Risk • May 24
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£1.2m free cash flow). Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 1.5% per year over the past 5 years. Revenue is less than US$1m (UK£2.0k revenue, or US$2.5k). Market cap is less than US$10m (UK£1.92m market cap, or US$2.45m). Minor Risk Shareholders have been diluted in the past year (15% increase in shares outstanding). Announcement • May 01
N4 Pharma Plc, Annual General Meeting, May 23, 2024 N4 Pharma Plc, Annual General Meeting, May 23, 2024, at 10:00 Coordinated Universal Time. Location: Shakespeare Martineau LLP, 6th Floor 60 Gracechurch Street London United Kingdom Agenda: To consider and approve the annual report and audited accounts for the year ended 31 December 2023; to consider and approve the election of Director; to consider and approve the re-appointment of the Saffery Champness LLP as the Company's auditor; and to consider and approve any other matters. New Risk • Mar 30
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 10% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (UK£1.75m market cap, or US$2.20m). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Shareholders have been diluted in the past year (15% increase in shares outstanding). Announcement • Jan 08
N4 Pharma plc Provides A Further Successful Update on Its Ongoing Research Work into the Use of Nuvec to Enhance the Performance of Viral Vector N4 Pharma Plc provided a further successful update on its ongoing research work into the use of Nuvec®? to enhance the performance of viral vectors. Through its research programme with the University of Brunel, the Company has demonstrated via a series of in vitro experiments that Nuvec®? can deliver increased transduction efficacy, when complexed with Adeno-Associated virus 8 ("AAV8"). This follows on from earlier work where the Company showed that Nuvec®? increased transduction efficacy of a standard Adenovirus vector. Specifically, Nuvec®? was mixed with AAV8 carrying a fluorescent green protein gene and used to transduce human-like liver cells (induced pluripotent cell model). When the viral vector was complexed with Nuvec®?, transduction efficacy increased 2.5-fold compared to the AAV8 vector when used on a standalone basis. AAV8 was chosen for investigation as this virus is currently being used for products already in clinical development. Announcement • Dec 18
N4 Pharma Plc Provides Positive Update on its Ongoing Oral Delivery Research Work N4 Pharma Plc provided a positive update on its ongoing oral delivery research work. The Company through its research program with the University of Queensland is evaluating the potential of Nuvec to act as an oral delivery system for oligonucleotides including DNA and RNA. Experiments have now confirmed, in vivo, the successful oral administration of Nuvec loaded with a DNA plasmid for ovalbumin. The Nuvec was administered by enteric coated capsule and the contents, having been released in the intestinal lumen, were taken up by intestinal cells, with successful transfection and release of the newly synthesized ovalbumin. Specifically, the first experiment was a repeat of a study conducted earlier this year whereby an enterically coated capsule containing Nuvec loaded with an DNA plasmid for ovalbin was administered and protein expression was observed after 3 days. In this recent experiment, an additional second capsule was administered on day 3 which resulted in a much higher peak level of expression on days 4-7. Announcement • Dec 07
N4 Pharma plc Provides an Encouraging Update on Its Ongoing in Vitro Sirna Research Work N4 Pharma Plc provide an encouraging update on its ongoing in vitro siRNA research work. The Company's double loaded siRNA work is ongoing and the Board wishes to provide an update on the progress achieved so far, as reach the end of 2023. The work to date is very encouraging and is demonstrating that Nuvec® has considerable potential to be able to knockdown two independent pathways leading to more effective cancer treatments by reducing the ability for tumour escape. For the past few months, the Company has been investigating the ability of Nuvec® nanoparticles to be loaded with, and deliver at the same time, two different siRNA known to inhibit relevant oncology targets. This is cutting edge research in the use of nanoparticles as delivery systems in oncology and consequently the Company is proceeding carefully to ensure that it gains the maximum understanding of the cellular processes involved. Using multiple different siRNA constructs has demonstrated that two separate siRNA can be loaded onto Nuvec®without changing the size or charge of Nuvec®, both parameters being essential for successful cellular uptake. The initial work on cell growth involved investigating the combination of inhibition ofEGFR (epidermal growth factor receptor) andBCL-2:(B-cell lymphoma 2) using PC-9 cancer cells. As previously announced, each siRNA when separately loaded onto Nuvec® achieved cell inhibition and an assay to measure BCL-2 had been established. Subsequent work has confirmed that the expression level of BCL-2 in PC9 cells was at the limits of detection, and consequently unlike with EGFR, a knockdown response curve could not be measured. In view of the low BCL-2 expression, the Company has been investigating alternative cellular pathways that may be inhibited using siRNA loaded alongside EGFR. The first was BRD4 (Bromodomain-containing-protein 4)a target for which inhibitors are currently being evaluated in clinical trials in uveal melanoma, leukemia and carcinoma. The second target was PLK1 (Polo Like Kinase 1), inhibitors of which are in early clinical trials for lymphoma and pancreatic cancer. Additional targets may also be explored as the Company's work progresses. New Risk • Sep 13
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -UK£1.3m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£1.3m free cash flow). Earnings have declined by 10% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (UK£3.16m market cap, or US$3.94m). Minor Risks Share price has been volatile over the past 3 months (8.7% average weekly change). Shareholders have been diluted in the past year (29% increase in shares outstanding). New Risk • Sep 08
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 17% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (UK£3.51m market cap, or US$4.37m). Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Share price has been volatile over the past 3 months (8.5% average weekly change). Shareholders have been diluted in the past year (29% increase in shares outstanding). Announcement • Jul 25
N4 Pharma plc Announces Executive Changes, Effect from 1 August 2023 N4 Pharma Plc announces that John Chiplin, currently Non-Executive Chairman, is retiring from the Board for personal reasons. Chris Britten, currently a Non-Executive Director of the Company, will assume the role of Non-Executive Chairman of N4 Pharma with effect from 1 August 2023. Announcement • Jan 18
N4 Pharma Plc Provides Oral Application Update N4 Pharma Plc provided an update on its ongoing Australian Research Council grant work with the University of Queensland, investigating the oral delivery of Nuvec® loaded with DNA. The Company has now completed two in vivo studies demonstrating that Nuvec loaded with OVA m-cherry DNA and encapsulated within an acid protective polymer can be dosed orally, penetrate the mucus layer and successfully express the OVA m-cherry locally in the intestine epithelial cells. In the first study Nuvec® was formulated together with the OVA and the whole formulation was coated with the polymer as a capsule. In the second study the nanoparticles, once loaded with OVA, were individually encapsulated with the polymer and administered via an oral gavage. Board Change • Nov 16
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Independent Non-Executive Chairman John Chiplin was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Board Change • Apr 27
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Chairman John Chiplin was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Feb 25
N4 Pharma Plc, Annual General Meeting, Mar 24, 2021 N4 Pharma Plc, Annual General Meeting, Mar 24, 2021, at 10:00 Coordinated Universal Time. Announcement • Feb 13
N4 Pharma plc Announces Notification of Intention to Grant Patent N4 Pharma Plc announced that the University of Queensland ("UQ") has been notified by the European Patent Office ("EPO") of its intention to grant a European Patent in relation to Nuvec® specifically in respect of its composition, particulate materials and methods for making the particulate materials (the "Patent"). N4 Pharma has the exclusive worldwide rights to Nuvec® for therapeutic uses in humans and animals. Having received the notification the next steps prior to formal grant will require UQ to confirm the particulars and translations with the EPO prior to publication of the grant after which the Patent will be validated on a country by country basis throughout Europe as determined by UQ and the Company. This process, resulting in the full grant of the Patent in each chosen territory, should take six to eight months. Announcement • Dec 04
N4 Pharma plc Provides the Following Update on Its Ongoing Research Collaboration Agreement with Nanomerics Limited N4 Pharma Plc announced to provide the following update on its ongoing research collaboration agreement with Nanomerics Limited. As announced on 11 February 2020, the Company initiated the first phase of research to test the stability of different formulations of Nuvec® loaded with a well characterised plasmid DNA. The Company reported that, in addition to not degrading the plasmid DNA, which it announced on 5 November 2020, Nuvec® formulations that had been freeze dried and then stored for 14 days either at room temperature or at four degrees Celsius, showed no significant drop in vitro transfection capability following reconstitution compared to fresh formulations. In parallel to continued work on analysing stability duration, different formulations will now be chosen to move forward into phase two of the work programme testing the efficacy of the dried and reconstituted plasmid DNA in an in vivo antibody generation model. 
